A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Vs Placebo for Symptomatic Treatment in Patients With Huntington's Disease

Inclusion Criteria

• •Diagnosis of HD based on the presence of \>/= 36 CAG repeats
• •Male or female age ≥21 years, with an onset of HD after 18 years' old.
• •Females of childbearing potential must be compliant in using adequate birth control throughout the duration of the study
• •Body weight ≥50 kg
• •Sum of \>= 25 points on the UHDRS-TMS and UHDRS Independence Score \<=90%
• •Able and willing to provide written informed consent prior to any study related procedure.
• •Willing to provide a blood sample for genetic analyses
• •Willing and able to take oral medication and able to comply with the study specific procedures.
• •Ambulatory, being able to travel to the study center, and judged by the investigator as likely to be able to continue to travel for the duration of the study.
• •Availability and willingness of a caregiver, informant or family member to accompany the patient to the clinic at study, and the suitability of the caregiver should be judged by the Investigator.
• •* Other criteria apply, please contact the investigator for more information.